Asciminib vs Other TKIs for Chronic Myeloid Leukemia
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called asciminib against other existing treatments for adults newly diagnosed with a specific type of leukemia. The goal is to see if asciminib is more effective at blocking a protein that helps cancer cells grow. Asciminib has shown superior efficacy in patients with chronic myeloid leukemia (CML) previously treated with multiple other treatments.
Do I need to stop my current medications to join the trial?
The trial does not specify if you need to stop taking your current medications. However, if you are on medications with a known risk of causing heart rhythm issues, you may need to stop or replace them 7 days before starting the study drug.
What data supports the effectiveness of the drug Asciminib for treating chronic myeloid leukemia?
Research shows that Asciminib is more effective and safer than bosutinib for patients with chronic myeloid leukemia who have already tried at least two other treatments. In a study, 37.6% of patients taking Asciminib achieved a significant reduction in cancer cells compared to 15.8% of those taking bosutinib, and fewer patients experienced severe side effects with Asciminib.12345
What is the safety profile of Asciminib for chronic myeloid leukemia?
What makes the drug Asciminib unique for treating chronic myeloid leukemia?
Asciminib is unique because it is the first drug to specifically target the ABL myristoyl pocket, offering a new mechanism of action for treating chronic myeloid leukemia, especially in patients who have not responded well to other treatments. It has shown superior efficacy and safety compared to bosutinib, making it a promising option for patients who have tried at least two other tyrosine kinase inhibitors.12347
Research Team
Novartis Pharmaceuticals
Principal Investigator
Novartis Pharmaceuticals
Eligibility Criteria
Adults over 18 with newly diagnosed Ph+ CML-CP within the last 3 months, who haven't been treated for it yet. They must have normal or correctable levels of certain blood elements and organ functions, no severe heart issues or other serious medical conditions, and an ECOG performance status of 0 or 1.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either asciminib or an Investigator selected TKI for the treatment of Ph+ CML-CP
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Asciminib
- Bosutinib
- Dasatinib
- Imatinib
- Nilotinib
Asciminib is already approved in United States, European Union for the following indications:
- Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) in adults previously treated with ≥2 tyrosine kinase inhibitors (TKIs)
- Ph+ CML in CP with the T315I mutation
- newly diagnosed Ph+ CML in CP
- Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) in adults previously treated with ≥2 tyrosine kinase inhibitors (TKIs)
- Ph+ CML in CP with the T315I mutation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD